Liver International,
Год журнала:
2022,
Номер
42(4), С. 742 - 748
Опубликована: Фев. 19, 2022
Polarizing
opinions
have
recently
arisen
in
hepatology
on
the
name
and
redefinition
of
fatty
liver
disease
associated
with
metabolic
dysfunction.
In
spite
growing
robust
evidence
superior
utility
term
(dysfunction)
(MAFLD)
definition
for
clinical
academic
practice,
controversy
abounds.
It
should
therefore
come,
as
no
surprise
that
most
common
arguments
used
contrarian
op-eds
is
there
are
consensus
any
change.
this
context,
we
suggest
discourse
an
accurate
understanding
what
scientific
means,
various
methods
achieving
consensus,
well
other
alternative
models
reaching
agreement
pivotal
field.
opinion
piece,
provide
overview
these
aspects
it
applies
to
case
disease.
We
a
change
from
non-alcoholic
(NAFLD)
MAFLD
has
already
been
achieved.
believe
time
come
redirecting
stakeholder
focus
energy
capitalizing
momentum
generated
by
debate
improve
lives
people
at
its
centre,
our
patients.
Therapeutic Advances in Endocrinology and Metabolism,
Год журнала:
2022,
Номер
13
Опубликована: Янв. 1, 2022
Metabolic
(dysfunction)-associated
fatty
liver
disease
(MAFLD)
is
the
most
common
chronic
worldwide
–
with
an
estimated
global
prevalence
of
37%.
Different
from
nonalcoholic
(NAFLD),
which
exclusion
diagnosis,
MAFLD
defined
by
a
set
positive
criteria.
This
recent
change
in
terminology
challenging
because
and
NAFLD
denote
two
similar,
albeit
not
identical,
clinical
populations.
When
diagnostic
criteria
for
are
applied,
histology
appears
more
severe
outcomes
less
favorable.
However,
management
remains
similar.
While
biopsy
still
reference
standard
achieving
final
noninvasive
imaging-
or
biomarker-based
modalities
currently
gaining
momentum.
should
be
recommended
when
challenges
exist.
In
this
review,
we
compared
epidemiology,
natural
history,
diagnosis
respect
to
traditional
definition.
Frontiers in Endocrinology,
Год журнала:
2023,
Номер
14
Опубликована: Фев. 20, 2023
The
associations
between
metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)
and
cancer
development,
especially
extrahepatic
cancers,
are
unknown.
aims
of
the
current
study
were
to
investigate
incidence
rates
MAFLD
analyze
development
cancers.This
historical
cohort
included
participants
who
underwent
ultrasonographic
detection
hepatic
steatosis
at
a
tertiary
hospital
in
China
from
January
2013
October
2021.
was
diagnosed
accordance
with
International
Expert
Consensus
Statement.
Cox
proportional
hazards
regression
modeling
used
assess
cancers.Of
47,801
participants,
16,093
(33.7%)
had
MAFLD.
During
total
follow-up
175,137
person-years
(median
3.3
years),
rate
group
higher
than
that
non-MAFLD
[473.5
vs.
255.1
per
100,000
person-years;
ratio
1.86;
95%
confidence
interval
(CI)
1.57-2.19].
After
adjustment
for
age,
gender,
smoking
status,
alcohol
moderately
associated
cancers
female
reproductive
system/organs
(labium,
uterus,
cervix,
ovary)
[hazard
(HR)
2.24;
CI
1.09-4.60],
thyroid
(HR
3.64;
1.82-7.30),
bladder
4.19;
1.15-15.27)
cohort.MAFLD
ovary),
thyroid,
cohort.
Alimentary Pharmacology & Therapeutics,
Год журнала:
2021,
Номер
53(10), С. 1080 - 1089
Опубликована: Март 22, 2021
The
World
Health
Organization
(WHO)
set
a
goal
to
eliminate
hepatitis
C
(HCV)
infection
globally
by
2030,
with
specific
targets
reduce
new
viral
infections
80%
and
related
deaths
65%.
However,
an
overlooked
aspect
that
may
hinder
these
efforts
is
the
impact
other
liver
diseases
could
have
continuing
drive
disease
progression
offset
beneficial
of
DAAs
on
end-stage
hepatocellular
carcinoma
(HCC).
In
particular,
decrease
in
HCV
prevalence
has
been
countered
marked
increase
metabolic-associated
fatty
(MAFLD).To
review
potential
interaction
MAFLD.We
reviewed
literature
relating
arrange
HCV,
metabolic
dysfunction
MAFLD.In
this
viewpoint,
international
experts
suggest
holistic
multidisciplinary
approach
for
management
growing
number
treated
patients
who
achieved
SVR,
taking
into
consideration
MAFLD
reducing
morbidity
mortality
people
had
HCV.This
will
strengthen
improve
continuum
care
cascade
disease(s)
holds
alleviate
cost
burden
disease;
quality
life
following
treatment.
Liver International,
Год журнала:
2022,
Номер
42(4), С. 742 - 748
Опубликована: Фев. 19, 2022
Polarizing
opinions
have
recently
arisen
in
hepatology
on
the
name
and
redefinition
of
fatty
liver
disease
associated
with
metabolic
dysfunction.
In
spite
growing
robust
evidence
superior
utility
term
(dysfunction)
(MAFLD)
definition
for
clinical
academic
practice,
controversy
abounds.
It
should
therefore
come,
as
no
surprise
that
most
common
arguments
used
contrarian
op-eds
is
there
are
consensus
any
change.
this
context,
we
suggest
discourse
an
accurate
understanding
what
scientific
means,
various
methods
achieving
consensus,
well
other
alternative
models
reaching
agreement
pivotal
field.
opinion
piece,
provide
overview
these
aspects
it
applies
to
case
disease.
We
a
change
from
non-alcoholic
(NAFLD)
MAFLD
has
already
been
achieved.
believe
time
come
redirecting
stakeholder
focus
energy
capitalizing
momentum
generated
by
debate
improve
lives
people
at
its
centre,
our
patients.
